Dr. Scott Rocklage of 5AM Ventures is an investor that makes very sound investment decisions within the evolving industry of healthcare. Dr. Scott Rocklage, certainly, possesses the background to make sound investment decisions. He is very specific and niche-oriented. He possesses an academic background as a chemist. He is ideally suitable in playing an investment leadership role at 5AM Ventures. It is correct to state that the biopharmaceutical industry provides a world of possibility as it pertains to idealized investment opportunities.
Dr. Scott Rocklage is at an advantage in that he has acquired academic training and relative experience, bringing to the investment table, a wealth of knowledge, in way of recognizing the correct pharmaceuticals that will make the healthcare future brighter: and the maintenance of certain maladies more manageable. The text which follows, provides information regarding Dr. Scott Rocklage’s highly-refined background:
Scott M. Rocklage, Ph.D. became a part of the team at 5AM Ventures in 2003. He began his tenure at 5AM Ventures as a Venture partner. He is now Managing Partner of the organization. He attained his current post in 2004.
Scott M. Rocklage, Ph.D. possesses thirty years of healthcare leadership and experience. He has attained great success by bringing 3 new medicines to the public—those being, Omniscan™, Teslascan® and Cubicin®.
Scott M. Rocklage, Ph.D has a most impressive leadership background. He served as CEO and Chairman of Cubist Pharmaceuticals. The organization is based in Lexington, Massachusetts. Its parent company is Merck. Scott M. Rocklage, Ph.D, additionally, served as the Chief Executive Officer of Nycomed Salutar—a diagnostic imaging organization. He has held R&D posts at Catalytica, and Salutar.
Scott M. Rocklage, Ph.D has served as the Board Chairman of Novira, and Relypsa. Novira was later acquired by J&J.
He is currently Board Chairman of: Cidara, Kinestral, and Rennovia. He, additionally, serves on the Boards of Pulmatrix, and Epirus.
Dr. Scott M. Rocklage was previous Executive Chairman of Ilypsa. The preceding company was taken over by Amgen. He, as well, served on the Boards of Semprus, which was acquired by Teleflex, and Miikana, which was acquired by EntreMed.
Academically-speaking, Dr. Rocklage attained his B.S. Degree, in Chemistry, from the University of California. He attained his Ph.D. from MIT. He has conducted research in the laboratory of Richard R. Schrock—a Nobel laureate.
The company which Scott M. Rocklage is a Managing Partner–5AM–makes it a point to strive for optimum levels of returns for the shareholder. The company provides redefinition to an investment strategy. It provides restructuring of management; with a great deal of emphasis placed on a positive level of investment performance; relative to the sector of healthcare.